Skip to content
10-K

Annual Report

TENAX THERAPEUTICS, INC. TENX

0001193125-26-099393

← back to feed
Filed
Mar 10, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 6, 2026 17.2M sh
Shares Diluted FY 2025 · Dec 31, 2025 39.22M sh
Shares Diluted FY 2025 · Dec 31, 2024 15.27M sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$35.8M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$14.81M
Cash And Equivalents FY 2025 · Dec 31, 2025 $97.6M
Cash And Equivalents FY 2025 · Dec 31, 2024 $94.9M
Stockholders Equity FY 2025 · Dec 31, 2025 $97.07M
Stockholders Equity FY 2025 · Dec 31, 2024 $91.99M
Stockholders Equity restated FY 2025 · Dec 31, 2023 $8.1M
Current Liabilities FY 2025 · Dec 31, 2025 $7.16M
Current Liabilities FY 2025 · Dec 31, 2024 $4.69M
Total Liabilities FY 2025 · Dec 31, 2025 $7.16M
Total Liabilities FY 2025 · Dec 31, 2024 $4.69M
Current Assets FY 2025 · Dec 31, 2025 $104.23M
Current Assets FY 2025 · Dec 31, 2024 $96.69M
Total Assets FY 2025 · Dec 31, 2025 $104.23M
Total Assets FY 2025 · Dec 31, 2024 $96.69M
Eps Diluted FY 2025 · Dec 31, 2025 −$1.34
Eps Diluted FY 2025 · Dec 31, 2024 −$1.15
Eps Basic FY 2025 · Dec 31, 2025 −$1.34
Eps Basic FY 2025 · Dec 31, 2024 −$1.15
Rd Expense FY 2025 · Dec 31, 2025 $32.67M
Rd Expense FY 2025 · Dec 31, 2024 $12.71M
Net Income FY 2025 · Dec 31, 2025 −$52.6M
Net Income FY 2025 · Dec 31, 2024 −$17.6M
Operating Income FY 2025 · Dec 31, 2025 −$56.39M
Operating Income FY 2025 · Dec 31, 2024 −$19.49M
Revenue FY 2025 · Dec 31, 2025 $0